Sunshine Biopharma, Inc.
NASDAQSBFM (Sunshine Biopharma) has seen one of the most dramatic lending-market dislocations in its history. In five trading days, the cost to borrow exploded from 17% to 561%. Short interest jumped 603% in a week to 13.6% of free float. A week ago, the borrow market was wide open. Availability stood at 1,295% — roughly 13 shares available for every…
SBFM cost to borrow explodes to 561.1% — up from 17.4% last week as short sellers pile in ahead of earnings.
SBFM (Sunshine Biopharma) has seen one of the most dramatic lending-market dislocations in its history. In five trading days, the cost to borrow exploded from 17% to 561%. Short interest jumped 603% in a week to 13.6%…
Sunshine Biopharma heads into its May 20 earnings event in the grip of one of the sharpest short-selling acceleration episodes its lending market has seen in over a year. The positioning story is stark. Short interest…
Snapshot as of 28 Jun 2026
Sunshine Biopharma heads into its May 20 earnings event with short sellers retreating sharply and borrow conditions markedly looser than they were six weeks ago. The short interest story is the clearest signal this…
SBFM heads into tomorrow's earnings report as a micro-cap biotech with a sliding stock, a shrinking short book, and a lending market that remains active but far from stressed. Short sellers have been covering steadily.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SBFM — free to start on ORTEX.
Sign up for free →Open SBFM on ORTEX